Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study

Table 1 List of compounds used as LAI treatment and their on– / off–label indications based on diagnoses in the study cohort

Pharmaceutical Compound	Dosage	Schizophrenia	Bipolar Disorder	Major depression	Obsessive compulsive Disorder	Personality Disorder	Neurodevelopmental Disorder	Neurocognitive Disorder	Other
Haloperidol Decanoate^a (FGA)	12,5–300 mg/monthly	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Zuclopenthixol Decanoate^b (FGA)	100–600 mg/biweekly	ON LABEL	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Fluphenazine Decanoate^c (FGA)	12,5–100 mg/biweekly	ON LABEL	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Risperidone LAI^d (SGA)	25–50 mg/biweekly	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Paliperidone Palmitate^d (SGA)	25–150 mg/monthly	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Olanzapine Pamoate^d (SGA)	300–405 mg/monthly	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL
Aripiprazole LAI^d (SGA)	400 mg/monthly	ON LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL	OFF LABEL

^aHaloperidol Decanoate is licensed for the maintenance treatment of Schizophrenia and Schizoaffective Disorder
^bZuclopenthixol Decanoate is licensed for acute and chronic Schizophrenia and other dissociative syndromes characterized by symptoms such as hallucination, agitation, psychomotor excitement, hostility, aggressiveness and affective disturbances. Manic phase of manic–depressive psychosis
^cFluphenazine decanoate is licensed for the treatment of Schizophrenia and manic syndromes
^dAll SGA LAIs are licensed for the maintenance treatment of adults diagnosed with Schizophrenia
All licensing information refers to the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), FGA First–Generation Antipsychotic, SGA Second–Generation Antipsychotic

ISSN: 1471-244X